GleamWall
中文EN

GALT GALECTIN THERAPEUTICS INC

Pharmaceutical Preparations · Nasdaq · SEC CIK 1133416 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY37.8%
TTM EPS YoY45.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-179.3%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets357.0%
Debt / equity—
Current ratio0.28x
Interest coverage-2.20x

Cash quality & payout

Operating cash flow / net income0.63x
Accruals ratio-66.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$1.56M$2.13M$2.23M$1.93M$2.61M$3.26M$6.49M$11.11M
SG&A expense$1.80M$1.85M$1.85M$1.43M$1.59M$1.36M$1.41M$1.32M
Operating income-$3.37M-$3.98M-$4.08M-$3.37M-$4.20M-$4.62M-$7.90M-$12.43M
Interest expense$786,000$2.00M$1.99M$1.94M$1.82M$1.83M$1.74M$1.73M
Net income-$3.53M-$9.11M-$5.05M-$5.50M-$8.18M-$7.52M-$9.63M-$11.97M
EPS (basic)-0.04-0.14-0.08—-0.13-0.12-0.15—
EPS (diluted)-0.04-0.14-0.08—-0.13-0.12-0.15—
Weighted avg. shares (diluted)89.62M65.88M65.78M—64.20M63.45M63.20M—
Balance sheet
Cash & equivalents$11.71M$13.27M$14.11M$17.72M$11.53M$13.77M$7.43M$15.12M
Current assets$12.90M$14.66M$15.69M$19.44M$12.73M$15.43M$9.29M$17.25M
PP&E, net———$0———$0
Total assets$13.01M$14.83M$15.76M$19.53M$12.87M$15.60M$9.53M$17.50M
Current liabilities$46.41M$151.62M$7.31M$8.03M$136.44M$10.77M$110.84M$35.41M
Total liabilities$46.45M$151.68M$146.00M$145.73M$136.44M$132.77M$121.79M$120.56M
Shareholders' equity-$35.16M-$138,575-$131.96M-$127.92M-$125.30M-$118.89M-$113.98M-$104.79M
Shares outstanding100.88M66.31M65.86M65.20M64.47M64.06M63.29M63.16M
Cash flow statement
Operating cash flow-$2.27M-$2.44M-$3.87M-$6.04M-$3.54M-$6.60M-$7.69M-$12.79M
Financing cash flow$702,000$1.60M$257,000$12.24M$1.30M$12.94M$0$851,000
Stock-based compensation$949,000$963,000$686,000$195,000$498,000$500,000$468,000$590,000

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.